Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Kína3. fázis

Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours

A legfontosabb adatok

Ki végzi
The First Affiliated Hospital of University of Science and Technology of China
Hol
Hefei (Kína)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
1395 fő, tervezett
Kezdés
2026. dec.
Várható befejezés
2029. ápr. 30.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Tenecteplase
  • Endovascular Treatment
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥18 years
  • Clinical diagnosis of acute ischemic stroke with a disabling deficit and baseline NIHSS score ≥6 before randomization
  • Pre-stroke modified Rankin Scale score ≤2
  • Randomization within 24 hours of symptom onset or last known well, including wake-up and unwitnessed stroke
  • Eligible for intravenous thrombolysis and endovascular thrombectomy according to the trial criteria
  • Written informed consent from the patient or a legal representative
  • Primary MeVO confirmed by computed tomography angiography or magnetic resonance angiography and responsible for the acute neurological deficit, involving the co-dominant or non-dominant M2 segment (occluded branch diameter ≤2.0 mm), M3, anterior cerebral artery A1-A3, or posterior cerebral artery P1-P3
  • Anterior circulation occlusion within 6 hours: established infarct extent <50% of the territory supplied by the occluded artery on non-contrast CT or diffusion-weighted MRI. For M2 or M3 occlusion, Alberta Stroke Program Early CT Score (ASPECTS) ≥6 is also required
  • Posterior circulation occlusion within 24 hours: posterior circulation ASPECTS (pc-ASPECTS) ≥8 and established infarct extent <50% of the territory supplied by the occluded artery on non-contrast CT or diffusion-weighted MRI
  • Anterior circulation occlusion at >6 to 24 hours, meeting either of the following imaging profiles: (a) established infarction involving <50% of the vascular territory corresponding to the clinical deficit on non-contrast CT or diffusion-weighted MRI; OR (b) target mismatch on CT or MR perfusion, defined as a mismatch volume >10 mL and a mismatch ratio >1.4

Ki nem vehet részt

  • Suspected or previous cerebral vasculitis or infective endocarditis, including suspected septic embolism
  • Use of a direct thrombin inhibitor or a direct factor Xa inhibitor within 48 hours, unless dabigatran has been reversed with idarucizumab
  • Current participation in another interventional clinical trial, or participation within the previous 3 months in a study involving an investigational drug or device that could affect the present study
  • Intracranial hemorrhage on CT or MRI; fewer than 10 cerebral microbleeds on MRI are permitted
  • Pre-existing neurological disease or psychiatric disorder that precludes reliable examination or follow-up assessment
  • Known allergy to tenecteplase or its excipients; a contraindication to contrast agents, such as severe contrast allergy; or known allergy to nickel-titanium alloys or other materials used in thrombectomy devices
  • Severe cardiac or hepatic dysfunction or another serious systemic disease with a life expectancy of less than 1 year
  • History of arteriovenous malformation or aneurysm; intracranial tumor
  • Seizure at stroke onset that precludes an accurate baseline NIHSS assessment, or Todd paresis
  • History of drug or alcohol abuse or dependence that, in the investigator's judgment, would interfere with adherence to study requirements
  • Contraindication to thrombolysis, including intracranial hemorrhage or acute ischemic stroke within the previous 3 months; intracranial surgery or severe head trauma within 3 months; any previous intracranial hemorrhage; clinically suspected subarachnoid hemorrhage; arterial puncture at a non-compressible site within 7 days; major surgery or serious trauma within 14 days; gastrointestinal or urinary tract hemorrhage within 21 days; active internal bleeding or an acute bleeding tendency; hereditary or acquired bleeding diathesis or clotting-factor deficiency; platelet count <100 × 10⁹/L; current therapeutic-dose heparin anticoagulation (including therapeutic-dose low-molecular-weight heparin within 24 hours); international normalized ratio >1.7 or prothrombin time >15 seconds after anticoagulant use; or full-dose heparin or heparinoid use within 24 hours with an activated partial thromboplastin time above the upper limit of normal
  • Blood glucose <2.8 or >22.2 mmol/L
  • Renal impairment with estimated glomerular filtration rate <30 mL/min/1.73 m² or creatinine >176.8 µmol/L, or a requirement for dialysis
  • Intravenous thrombolysis already administered at a referring center
  • Rapidly improving neurological deficit, as judged by the investigator
  • Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg despite antihypertensive treatment
  • Medium vessel occlusion arising from distal migration or fragmentation of a more proximal thrombus, whether spontaneous, after intravenous thrombolysis, or during endovascular thrombectomy
  • Established infarction involving the arterial territory proximal to the target occlusion
  • Hypodensity on non-contrast CT exceeding the perfusion lesion, suggesting distal thrombus migration
  • Severe tortuosity, anatomical variant, or dissection precluding device access to the target vessel
  • Simultaneous occlusion in more than one vascular territory, such as anterior and posterior circulation occlusion or bilateral anterior circulation occlusion
  • Pregnancy or breastfeeding, or a positive pregnancy test before enrollment in a woman of childbearing potential
  • Inability to complete the 90-day follow-up (e.g., no fixed residence or living overseas)
  • Prisoners or incarcerated persons

Helyszínek itt: Kína

  • The First Affiliated Hospital of University of Science and Technology of ChinaHefei, KínaContact: Wei Hu, MD, PhDToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This trial compares intravenous thrombolysis (IVT) alone, endovascular treatment (EVT) alone, and bridging therapy (IVT followed immediately by EVT) in patients with acute ischemic stroke due to medium vessel occlusion (MeVO) and a baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6. The hypotheses are that EVT alone and bridging therapy each increase the proportion of patients with functional independence at 90 days compared with IVT alone. This is a multicenter, prospective, randomized, open-label trial with blinded outcome assessment. Patients will be randomized 1:1:1 within 24 hours of symptom onset or last known well. The primary outcome is functional independence, defined as a modified Rankin Scale (mRS) score of 0 to 2 at 90 days.

A vizsgálat 3 csoportja

  • IVT AloneMár használt kezelés, összehasonlításként

    Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus. Endovascular treatment is not performed.

    Kezelés: Tenecteplase

  • EVT AloneA vizsgált kezelés

    Participants receive endovascular treatment without intravenous thrombolysis.

    Kezelés: Endovascular Treatment

  • Bridging IVT Plus EVTA vizsgált kezelés

    Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus, followed immediately by endovascular treatment.

    Kezelés: Tenecteplase és Endovascular Treatment

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Thrombolysis, Thrombectomy, or Bridging Therapy for Acute Medium Vessel Occlusion Within 24 Hours: A Multicenter, Three-Arm, Randomized Controlled Trial
A regiszteradat frissítve
2026. november 12.